Data / Form D filings / Telemachus Therapeutics, Inc.
Telemachus Therapeutics, Inc.: Form D filings
Telemachus Therapeutics, Inc., a pharmaceuticals company in Wexford, PA, filed 2 Form D notices with the SEC in 2026. The latest, on October 28, 2026, reports $375,000 sold of a $1.5 million offering to 3 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 401 WOODHAVEN DRIVE, Wexford, PA, 15090
- Phone
- (412) 527-6630
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2026
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2152986
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 28, 2026 | Amendment | $1,500,000 | $375,000 | $1,125,000 | 3 | Aug 20, 2026 | sec.gov |
| Sep 2, 2026 | New notice | $1,500,000 | $125,000 | $1,375,000 | 1 | Aug 20, 2026 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Michael Bozik | Executive Officer, Director, Promoter | |
| Gregory Hebrank | Executive Officer, Director, Promoter |
Other pharmaceuticals companies in Pennsylvania that filed recently
- EpiVario Inc. $185,000 · Oct 13, 2026
- Maxona Pharmaceuticals, Inc. $5.8 million · Aug 14, 2026
- PLEOPHARMA, INC. $5.5 million · Aug 10, 2026
- Duo Oncology Inc. $1.6 million · Aug 7, 2026
Every Form D from the week of Oct 26, 2026 · All recent filings in Pennsylvania · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Telemachus Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.